Atria Wealth Solutions Inc. Has $350,000 Position in Quest Diagnostics Incorporated (NYSE:DGX)

Atria Wealth Solutions Inc. reduced its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 32.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,067 shares of the medical research company’s stock after selling 1,008 shares during the period. Atria Wealth Solutions Inc.’s holdings in Quest Diagnostics were worth $350,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in Quest Diagnostics in the 4th quarter valued at $323,000. Federated Hermes Inc. raised its holdings in Quest Diagnostics by 232.3% in the 4th quarter. Federated Hermes Inc. now owns 1,233 shares of the medical research company’s stock valued at $186,000 after acquiring an additional 862 shares in the last quarter. Townsquare Capital LLC raised its holdings in Quest Diagnostics by 59.7% in the 4th quarter. Townsquare Capital LLC now owns 2,649 shares of the medical research company’s stock valued at $400,000 after acquiring an additional 990 shares in the last quarter. Mariner LLC raised its holdings in Quest Diagnostics by 4.8% in the 4th quarter. Mariner LLC now owns 52,153 shares of the medical research company’s stock valued at $7,868,000 after acquiring an additional 2,380 shares in the last quarter. Finally, CreativeOne Wealth LLC raised its holdings in Quest Diagnostics by 21.3% in the 4th quarter. CreativeOne Wealth LLC now owns 6,480 shares of the medical research company’s stock valued at $977,000 after acquiring an additional 1,137 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

Quest Diagnostics Trading Up 0.7%

NYSE DGX opened at $179.67 on Friday. The business’s 50-day moving average price is $174.68 and its two-hundred day moving average price is $171.73. Quest Diagnostics Incorporated has a 12 month low of $146.17 and a 12 month high of $182.38. The firm has a market capitalization of $20.09 billion, a PE ratio of 21.52, a price-to-earnings-growth ratio of 2.37 and a beta of 0.46. The company has a current ratio of 1.09, a quick ratio of 0.99 and a debt-to-equity ratio of 0.71.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.05. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%. The firm had revenue of $2.76 billion for the quarter, compared to analyst estimates of $2.73 billion. During the same quarter in the previous year, the company posted $2.35 EPS. The business’s revenue was up 15.2% on a year-over-year basis. On average, analysts expect that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 20th. Stockholders of record on Friday, October 3rd will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Friday, October 3rd. Quest Diagnostics’s payout ratio is currently 38.32%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. UBS Group dropped their price objective on Quest Diagnostics from $176.00 to $175.00 and set a “neutral” rating for the company in a report on Friday, July 18th. Truist Financial lifted their price target on Quest Diagnostics from $190.00 to $192.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. Wall Street Zen lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Sunday, August 10th. Piper Sandler lifted their price target on Quest Diagnostics from $180.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, April 28th. Finally, Barclays lifted their price target on Quest Diagnostics from $175.00 to $185.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $186.00.

Insider Transactions at Quest Diagnostics

In other news, SVP Patrick Plewman sold 5,535 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $175.00, for a total value of $968,625.00. Following the transaction, the senior vice president directly owned 19,219 shares of the company’s stock, valued at $3,363,325. The trade was a 22.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Karthik Kuppusamy sold 8,269 shares of the business’s stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $167.40, for a total value of $1,384,230.60. Following the completion of the transaction, the senior vice president directly owned 10,660 shares in the company, valued at $1,784,484. This represents a 43.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,014 shares of company stock worth $2,728,556 over the last three months. 8.16% of the stock is owned by company insiders.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.